Metabolism of bioconjugate therapeutics: why, when, and how?

References

• Abu Ajaj K, El-Abadla N, Welker P, Azab S, Zeisig R, Fichtner I, Kratz F. 2012. Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative. Eur J Cancer. 48:2054–2065.
   PubMed Web of Science ®Google Scholar
• Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA. 2012. Antibody-drug conjugates – a perfect synergy. Expert Opin Biol Ther. 12:1191–1206.
   PubMed Web of Science ®Google Scholar
• Albin N, Massaad L, Toussaint C, Mathieu MC, Morizet J, Parise O, Gouyette A, Chabot GG. 1993. Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res. 53:3541–3546.
   PubMed Web of Science ®Google Scholar
• Ambrosio AJ, Suzin D, Palmer EL, Penson RT. 2014. Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer. Expert Rev Clin Pharmacol. 7:443–450.
   PubMed Web of Science ®Google Scholar
• Amitay Y, Shmeeda H, Patil Y, Gorin J, Tzemach D, Mak L, Ohana P, Gabizon A. 2016. Pharmacologic studies of a prodrug of mitomycin C in pegylated liposomes (Promitil(®)): high stability in plasma and rapid thiolytic prodrug activation in tissues. Pharm Res. 33:686–700.
   PubMed Web of Science ®Google Scholar
• Anighoro A, Bajorath J, Rastelli G. 2014. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 57:7874–7887.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, Corvaïa N. 2017. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 16:315–337.
   PubMed Web of Science ®Google Scholar
• Bergman AM, Adema AD, Balzarini J, Bruheim S, Fichtner I, Noordhuis P, Fodstad O, Myhren F, Sandvold ML, Hendriks HR, et al. 2011. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs. 29:456–466.
   PubMed Web of Science ®Google Scholar
• Bessire AJ, Ballard TE, Charati M, Cohen J, Green M, Lam MH, Loganzo F, Nolting B, Pierce B, Puthenveetil S, et al. 2016. Determination of antibody-drug conjugate released payload species using directed in vitro assays and mass spectrometric interrogation. Bioconjugate Chem. 27:1645–1654.
   PubMed Web of Science ®Google Scholar
• Birdsall RE, McCarthy SM, Janin-Bussat MC, Perez M, Haeuw JF, Chen W, Beck A. 2016. A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection. MAbs. 8:306–317.
   PubMed Web of Science ®Google Scholar
• Bouchard H, Viskov C, Garcia-Echeverria C. 2014. Antibody-drug conjugates – a new wave of cancer drugs. Bioorg Med Chem Lett. 24:5357–5363.
   PubMed Web of Science ®Google Scholar
• Breistøl K, Balzarini J, Sandvold ML, Myhren F, Martinsen M, De Clercq E, Fodstad O. 1999. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res. 59:2944–2949.
   PubMed Web of Science ®Google Scholar
• Burke PJ, Hamilton JZ, Jeffrey SC, Hunter JH, Doronina SO, Okeley NM, Miyamoto JB, Anderson ME, Stone IJ, Ulrich ML, et al. 2017. Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates. Mol Cancer Ther. 16:116–123.
   PubMed Web of Science ®Google Scholar
• Burke PJ, Hamilton JZ, Pires TA, Setter JR, Hunter JH, Cochran JH, Waight AB, Gordon KA, Toki BE, Emmerton KK, et al. 2016. Development of novel quaternary ammonium linkers for antibody-drug conjugates. Mol Cancer Ther. 15:938–945.
   PubMed Web of Science ®Google Scholar
• Caculitan NG, Dela Cruz Chuh J, Ma Y, Zhang D, Kozak KR, Liu Y, Pillow TH, Sadowsky J, Cheung TK, Phung Q, et al. 2017. Cathepsin B is dispensable for cellular processing of Cathepsin B-cleavable antibody-drug conjugates. Cancer Res. 77:7027–7037.
   PubMed Web of Science ®Google Scholar
• Chen B, Dai W, He B, Zhang H, Wang X, Wang Y, Zhang Q. 2017. Current multistage drug delivery systems based on the tumor microenvironment. Theranostics. 7:538–558.
   PubMed Web of Science ®Google Scholar
• Citrome L. 2016. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol. 9:169–186.
   PubMed Web of Science ®Google Scholar
• Davis JA, Rock DA, Wienkers LC, Pearson JT. 2012. In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. Drug Metab Dispos. 40:1927–1934.
   PubMed Web of Science ®Google Scholar
• Diamantis N, Banerji U. 2016. Antibody-drug conjugates-an emerging class of cancer treatment. Br J Cancer. 114:362–367.
   PubMed Web of Science ®Google Scholar
• Dokter W, Ubink R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, Loosveld E, van den Dobbelsteen D, Egging D, Mattaar E, et al. 2014. Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform. Mol Cancer Ther. 13:2618–2629.
   PubMed Web of Science ®Google Scholar
• Donovan JM, Zimmer M, Offman E, Grant T, Jirousek M. 2017. A novel NF-κB inhibitor, edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients with duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects. J Clin Pharmacol. 57:627–639.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, et al. 2006. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjugate Chem. 17:114–124.
   PubMed Web of Science ®Google Scholar
• Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, Delaria K, Lui V, Poulsen K, Loo C, et al. 2015. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjugate Chem. 26:650–659.
   PubMed Web of Science ®Google Scholar
• Duncan R. 2017. Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century. J Drug Target. 25:759–780.
   PubMed Web of Science ®Google Scholar
• Effenberger K, Breyer S, Schobert R. 2010. Modulation of doxorubicin activity in cancer cells by conjugation with fatty acyl and terpenyl hydrazones. Eur J Med Chem. 45:1947–1954.
   PubMed Web of Science ®Google Scholar
• Egusquiaguirre SP, Igartua M, Hernández RM, Pedraz JL. 2012. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol. 14:83–93.
   PubMed Web of Science ®Google Scholar
• Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, de Groot FM, van der Lee MM, Ubink R, van den Dobbelsteen DJ, et al. 2015. Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985. Mol Pharm. 12:1813–1835.
   PubMed Web of Science ®Google Scholar
• Erickson HK, Lambert JM. 2012. ADME of antibody-maytansinoid conjugates. Aaps J. 14:799–805.
   PubMed Web of Science ®Google Scholar
• Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA. 2006. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66:4426–4433.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency (EMA). 2018. Mylotarg. [accessed 2018 Feb 22]. https://www.ema.europa.eu/en/documents/assessment-report/mylotarg-epar-public-assessment-report_en.pdf.
   Google Scholar
• Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811.
   PubMed Web of Science ®Google Scholar
• Friman S, Egestad B, Sjövall J, Svanvik J. 1993. Hepatic excretion and metabolism of polyethylene glycols and mannitol in the cat. J Hepatol. 17:48–55.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Amitay Y, Tzemach D, Gorin J, Shmeeda H, Zalipsky S. 2012. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. J Control Release. 160:245–253.
   PubMed Web of Science ®Google Scholar
• Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S. 2006. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin Cancer Res. 12:1913–1920.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Myhren F, Sandvold ML. 2009. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol. 144:273–275.
   PubMed Web of Science ®Google Scholar
• Gilat T, Leikin-Frenkel A, Goldiner L, Laufer H, Halpern Z, Konikoff FM. 2001. Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice. Lipids. 36:1135–1140.
   PubMed Web of Science ®Google Scholar
• Gilday E, Nasrallah HA. 2012. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. RRCT. 7:2–9.
   Google Scholar
• Gokhale M, Thakur A, Rinaldi F. 2013. Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent. Drug Dev Ind Pharm. 39:1315–1327.
   PubMed Web of Science ®Google Scholar
• Govindan SV, Cardillo TM, Rossi EA, Trisal P, McBride WJ, Sharkey RM, Goldenberg DM. 2015. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 12:1836–1847.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. 2004. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 351:2805–2816.
   PubMed Web of Science ®Google Scholar
• Haahr H, Heise T. 2014. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 53:787–800.
   PubMed Web of Science ®Google Scholar
• Hackett MJ, Zaro JL, Shen WC, Guley PC, Cho MJ. 2013. Fatty acids as therapeutic auxiliaries for oral and parenteral formulations. Adv Drug Deliv Rev. 65:1331–1339.
   PubMed Web of Science ®Google Scholar
• Hammers DW, Sleeper MM, Forbes SC, Coker CC, Jirousek MR, Zimmer M, Walter GA, Sweeney HL. 2016. Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle. JCI Insight. 1:e90341.
   PubMed Web of Science ®Google Scholar
• Han S, Hu L, Gracia Quach T, Simpson JS, Edwards GA1, Trevaskis NL, Porter CJ. 2016. Lymphatic transport and lymphocyte targeting of a triglyceride mimetic prodrug is enhanced in a large animal model: studies in greyhound dogs. Mol Pharm. 13:3351–3361.
   PubMed Web of Science ®Google Scholar
• Han S, Hu L, Quach T, Simpson JS, Trevaskis NL, Porter CJ. 2015. Profiling the role of deacylation-reacylation in the lymphatic transport of a triglyceride-mimetic prodrug. Pharm Res. 32:1830–1844.
   PubMed Web of Science ®Google Scholar
• Han S, Quach T, Hu L, Wahab A, Charman WN, Stella VJ, Trevaskis NL, Simpson JS, Porter CJ. 2014. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. J Control Release. 177:1–10.
   PubMed Web of Science ®Google Scholar
• Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM, et al. 2013. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol. 53:866–877.
   PubMed Web of Science ®Google Scholar
• Harb WA, Conley BA, LoRusso P, Sausville EA, Heath EI, Chandana SR, Hamm M, Carter J, Perez WJ, Messmann RA. 2010. A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer. J Clin Oncol. 28:3088.
   Web of Science ®Google Scholar
• Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L. 2017. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 37:289–295.
   PubMed Web of Science ®Google Scholar
• Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, Oberg AL, Low PS. 2007. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer. 121:938–942.
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Takada K, Kiso Y, Muranishi S. 1989. Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm Res. 06:171–176.
   Web of Science ®Google Scholar
• He J, Su D, Ng C, Liu L, Yu SF, Pillow TH, Del Rosario G, Darwish M, Lee BC, Ohri R, et al. 2017. High-resolution accurate-mass mass spectrometry enabling in-depth characterization of in vivo biotransformations for intact antibody-drug conjugates. Anal Chem. 89:5476–5483.
   PubMed Web of Science ®Google Scholar
• He YL, Murby S, Warhurst G, Gifford L, Walker D, Ayrton J, Eastmond R, Rowland M. 1998. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci. 87:626–633.
   PubMed Web of Science ®Google Scholar
• Hermanson GT. 2013. Bioconjugate techniques. Amsterdam (The Netherlands): Elsevier.
   Google Scholar
• Hostetler KY, Parker S, Sridhar CN, Martin MJ, Li JL, Stuhmiller LM, van Wijk GM, van den Bosch H, Gardner MF, Aldern KA. 1993. Acyclovir diphosphate dimyristoylglycerol: a phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus. Proc Natl Acad Sci USA. 90:11835–11839.
   PubMed Web of Science ®Google Scholar
• Huang Y. 2017. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids. 6:116–132.
   PubMedGoogle Scholar
• Irby D, Du C, Li F. 2017. Lipid-drug conjugate for enhancing drug delivery. Mol Pharm. 14:1325–1338.
   PubMed Web of Science ®Google Scholar
• Jackson D, Stover D. 2015. Using the lessons learned from the clinic to improve the preclinical development of antibody drug conjugates. Pharm Res. 32:3458–3469.
   PubMed Web of Science ®Google Scholar
• Jevsevar S, Kunstelj M, Porekar VG. 2010. PEGylation of therapeutic proteins. Biotechnol J. 5:113–128.
   PubMed Web of Science ®Google Scholar
• Johnson TR, Bessire AJ, Gleave M, Nedderman ANR, Kavosi M, Ballard TE. 2018. Characterization of the pharmacokinetics and disposition of inotuzumab ozogamicin, a calicheamicin-containing antibody-drug conjugate. Paper presented at: 21st North American ISSX Meeting; September 24–28; Providence, RI.
   Google Scholar
• Jones MC, Patel M. 2006. Insulin detemir: a long-acting insulin product. Am J Health Syst Pharm. 63:2466–2472.
   PubMed Web of Science ®Google Scholar
• Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. 2008. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 108:619–626.
   PubMed Web of Science ®Google Scholar
• Kamath AV, Iyer S. 2015. Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm Res. 32:3470–3479.
   PubMed Web of Science ®Google Scholar
• Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, et al. 2011. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjugate Chem. 22:717–727.
   PubMed Web of Science ®Google Scholar
• Kern JC, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, Figueroa I, Hsieh S, Liang L, Tomazela D, et al. 2016. Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody-drug conjugates. J Am Chem Soc. 138:1430–1445.
   PubMed Web of Science ®Google Scholar
• Kozlowski A, Harris JM. 2001. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release. 72:217–224.
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Eugène T, Pallardy A, Frampas E, Carlier T, Ferrer L, Gaschet J, Davodeau F, et al. 2014. Radioimmunoconjugates for the treatment of cancer. Semin Oncol. 41:613–622.
   PubMed Web of Science ®Google Scholar
• Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, Lazar P, Drückes P, Esser N, Drevs J, Rognan D, et al. 2002. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem. 45:5523–5533.
   PubMed Web of Science ®Google Scholar
• Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, Datta-Mannan A, Sriraman P, Bairlein M, Yang JJ, et al. 2016. Current approaches for absorption, distribution, metabolism, and excretion characterization of antibody-drug conjugates: an industry white paper. Drug Metab Dispos. 44:617–623.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. 2011. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 17:6398–6405.
   PubMed Web of Science ®Google Scholar
• Kumar S, King LE, Clark TH, Gorovits B. 2015. Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays. Bioanalysis. 7:1605–1617.
   PubMed Web of Science ®Google Scholar
• Lambert DM. 2000. Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci. 11:S15–S27.
   PubMed Web of Science ®Google Scholar
• Lamberts LE, Williams SP, Terwisscha van Scheltinga AG, Lub-de Hooge MN, Schröder CP, Gietema JA, Brouwers AH, de Vries EG. 2015. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol. 33:1491–1504.
   PubMed Web of Science ®Google Scholar
• Lanier ER, Ptak RG, Lampert BM, Keilholz L, Hartman T, Buckheit RW Jr, Mankowski MK, Osterling MC, Almond MR, Painter GR. 2010. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob Agents Chemother. 54:2901–2909.
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA, Klein PJ, Vlahov IR, Dorton R, Bloomfield A, Nelson M, Westrick E, Parker N, Bruna K, et al. 2011. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications. J Pharmacol Exp Ther. 336:336–343.
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA, Vlahov IR, Westrick E, Dawson A, Dorton R, Vetzel M, Santhapuram HK, Wang Y. 2007. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm. 4:659–667.
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, et al. 2008. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68:9280–9290.
   PubMed Web of Science ®Google Scholar
• Li F, Mahato RI. 2017. Bioconjugate therapeutics: current progress and future perspective. Mol Pharm. 14:1321–1324.
   PubMed Web of Science ®Google Scholar
• Li F, Snow-Davis C, Du C, Bondarev ML, Saulsbury MD, Heyliger SO. 2016. Preparation and characterization of lipophilic doxorubicin pro-drug micelles. J Vis Exp.
   Web of Science ®Google Scholar
• Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, LoRusso P. 2009. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol. 49:1467–1476.
   PubMed Web of Science ®Google Scholar
• Liang CH, Ye WL, Zhu CL, Na R, Cheng Y, Cui H, Liu DZ, Yang ZF, Zhou SY. 2014. Synthesis of doxorubicin α-linolenic acid conjugate and evaluation of its antitumor activity. Mol Pharm. 11:1378–1390.
   PubMed Web of Science ®Google Scholar
• Liu H, Ting A, Lee D, Zimmer M, Wachtel D, Dagher R, Mancini M, Donovan J, Liu F, Greene R, et al. 2017. In vitro and in vivo metabolite profiling and identification of edasalonexent (CAT-1004), a bioconjugate of salicylic acid (SA) and docosahexaenoic acid (DHA) using SMART linker technology. Poster session presented at: New England Drug Metabolism Discussion Group and International Consortium Drug Metabolism Leadership Group Joint Summer Symposium; May 31; Waltham, MA.
   Google Scholar
• Liu R, Wang RE, Wang F. 2016. Antibody-drug conjugates for non-oncological indications. Expert Opin Biol Ther. 16:591–593.
   PubMed Web of Science ®Google Scholar
• Liu Z, Floss HG, Cassady JM, Chan KK. 2005. Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. J Mass Spectrom. 40:389–399.
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Edelman MJ, Bever SL, Forman KM, Pilat M, Quinn MF, Li J, Heath EI, Malburg LM, Klein PJ, et al. 2012. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol. 30:4011–4016.
   PubMed Web of Science ®Google Scholar
• Lu J, Jiang F, Lu A, Zhang G. 2016. Linkers having a crucial role in antibody-drug conjugates. Int J Mol Sci. 17:561.
   PubMed Web of Science ®Google Scholar
• Maeda H. 2010. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjugate Chem. 21:797–802.
   PubMed Web of Science ®Google Scholar
• Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, van Lier JJ, Zdravkovic M, Olsen AK. 2010. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 38:1944–1953.
   PubMed Web of Science ®Google Scholar
• Mantaj J, Jackson PJ, Rahman KM, Thurston DE. 2017. From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs). Angew Chem Int Ed Engl. 56:462–488.
   PubMed Web of Science ®Google Scholar
• McCombs JR, Owen SC. 2015. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. Aaps J. 17:339–351.
   PubMed Web of Science ®Google Scholar
• Moldenhauer G, Salnikov AV, Lüttgau S, Herr I, Anderl J, Faulstich H. 2012. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst. 104:622–634.
   PubMed Web of Science ®Google Scholar
• Myers SR, Yakubu-Madus FE, Johnson WT, Baker JE, Cusick TS, Williams VK, Tinsley FC, Kriauciunas A, Manetta J, Chen VJ. 1997. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes. 46:637–642.
   PubMed Web of Science ®Google Scholar
• Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, et al. 2013. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 31:4400–4406.
   PubMed Web of Science ®Google Scholar
• Needs CJ, Brooks PM. 1985. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet. 10:164–177.
   PubMed Web of Science ®Google Scholar
• Newman RA, Fuentes A, Covey JM, Benvenuto JA. 1994. Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128). Drug Metab Dispos. 22:428–432.
   PubMed Web of Science ®Google Scholar
• Nichols A, Reilly J, Liu F, Bista P, Lee D, Webb S, Picarella D, Wood J, Yao M, Passini M, et al. 2017. Edasalonexent (CAT-1004), an NF-ĸB inhibitor, enhances myotube formation in vitro, and increases exon-skipped sarcolemmal dystrophin in muscle of mdx mice. Paper presented at: 22nd International Congress of the World Muscle Society; Oct 3–7; St. Malo, France.
   Google Scholar
• Palakurthi S. 2015. Challenges in SN38 drug delivery: current success and future directions. Expert Opin Drug Deliv. 12:1911–1921.
   PubMed Web of Science ®Google Scholar
• Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM, Lieberman J. 2006. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 439(7072):89–94.
   PubMed Web of Science ®Google Scholar
• Pandyarajan V, Weiss MA. 2012. Design of non-standard insulin analogs for the treatment of diabetes mellitus. Curr Diab Rep. 12:697–704.
   PubMed Web of Science ®Google Scholar
• Patil Y, Amitay Y, Ohana P, Shmeeda H, Gabizon A. 2016. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: intracellular activation and enhanced cytotoxicity. J Control Release. 225:87–95.
   PubMed Web of Science ®Google Scholar
• Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, et al. 2015. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 33:321–331.
   PubMed Web of Science ®Google Scholar
• Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM. 2014. Antibody-drug conjugates: current status and future directions. Drug Discov Today. 19:869–881.
   PubMed Web of Science ®Google Scholar
• Pickin KA, Alexander RL, Morrow CS, Morris-Natschke SL, Ishaq KS, Fleming RA, Kucera GL. 2009. Phospholipid/deoxycytidine analogue prodrugs for the treatment of cancer. J Drug Del Sci Tech. 19 :31–36.
   Web of Science ®Google Scholar
• Pillow TH, Schutten M, Yu SF, Ohri R, Sadowsky J, Poon KA, Solis W, Zhong F, Del Rosario G, Go MAT, et al. 2017. Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody-drug conjugates with self-immolative disulfide linkers. Mol Cancer Ther. 16:871–878.
   PubMed Web of Science ®Google Scholar
• Reddy JA, Dorton R, Dawson A, Vetzel M, Parker N, Nicoson JS, Westrick E, Klein PJ, Wang Y, Vlahov IR, et al. 2009. In vivo structural activity and optimization studies of folate-tubulysin conjugates. Mol Pharm. 6:1518–1525.
   PubMed Web of Science ®Google Scholar
• Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, Vlahov I, Chari RV, Goldmacher VS, Leamon CP. 2007. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res. 67:6376–6382.
   PubMed Web of Science ®Google Scholar
• Reilly JF, Liu H, Bista P, Wachtel D, Chandran S, Dagher R, Picarella D, Mancini M, Fretzen A, Donovan J, et al. 2017. Edasalonexent dosing regimen: preclinical modeling and clinical translation. Paper presented at: The 15th Action Duchenne International Conference 2017; Nov 10–12; Birmingham, UK.
   Google Scholar
• Rock BM, Tometsko ME, Patel SK, Hamblett KJ, Fanslow WC, Rock DA. 2015. Intracellular catabolism of an antibody drug conjugate with a noncleavable linker. Drug Metab Dispos. 43:1341–1344.
   PubMed Web of Science ®Google Scholar
• Rohde MM, Rk N, Håkansson AE, Jensen KG, Pedersen H, Dige TJ, Rgensen EB, Holm R. 2014. Biological conversion of aripiprazole lauroxil – an N-acyloxymethyl aripiprazole prodrug. Results Pharm Sci. 4:19–25.
   PubMedGoogle Scholar
• Roots Analysis Private Ltd. 2017–2030. Antibody drug conjugates market. 4th ed. Lyon (France): ReportLinker.
   Google Scholar
• Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjić N. 1998. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem. 273:20556–20567.
   PubMed Web of Science ®Google Scholar
• Saad OM, Shen BQ, Xu K, Khojasteh SC, Girish S, Kaur S. 2015. Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates. Bioanalysis. 7:1583–1604.
   PubMed Web of Science ®Google Scholar
• Salfeld JG. 2007. Isotype selection in antibody engineering. Nat Biotechnol. 25:1369–1372.
   PubMed Web of Science ®Google Scholar
• Sandvold ML, Galmarini C, Myhren F, Peters G. 2010. The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues. Nucleosides Nucleotides Nucleic Acids. 29:386–393.
   PubMed Web of Science ®Google Scholar
• Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S. 2013. Clinical utility of insulin and insulin analogs. Islets. 5:67–78.
   PubMed Web of Science ®Google Scholar
• Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. 2011. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs. 20:1131–1149.
   PubMed Web of Science ®Google Scholar
• Sapra P, Shor B. 2013. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 138:452–469.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Fukumoto M, Hashida M, Kimura T, Sezaki H. 1983. Development of lipophilic prodrugs of mitomycin C. III. Physiochemical and biological properties of newly synthesized alkoxycarbonyl derivatives. Chem Pharm Bull (Tokyo). 31(11):4083–4090.
   PubMed Web of Science ®Google Scholar
• Schellekens H, Hennink WE, Brinks V. 2013. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res. 30:1729–1734.
   PubMed Web of Science ®Google Scholar
• Senter PD, Sievers EL. 2012. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 30:631–637.
   PubMed Web of Science ®Google Scholar
• Shadid M, Bowlin S, Bolleddula J. 2017. Catabolism of antibody drug conjugates and characterization methods. Bioorg Med Chem. 25:2933–2945.
   PubMed Web of Science ®Google Scholar
• Shefet-Carasso L, Benhar I. 2015. Antibody-targeted drugs and drug resistance–challenges and solutions. Drug Resist Updat. 18:36–46.
   PubMed Web of Science ®Google Scholar
• Shen BQ, Bumbaca D, Yue Q, Saad O, Tibbitts J, Khojasteh SC, Girish S. 2015. Non-clinical disposition and metabolism of DM1, a component of trastuzumab emtansine (T-DM1), in Sprague Dawley rats. Drug Metab Lett. 9:119–131.
   PubMedGoogle Scholar
• Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, et al. 2012. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 30:184–189.
   PubMed Web of Science ®Google Scholar
• Sherman MR, Saifer MG, Perez-Ruiz F. 2008. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 60:59–68.
   PubMed Web of Science ®Google Scholar
• Shia J, Klimstra DS, Nitzkorski JR, Low PS, Gonen M, Landmann R, Weiser MR, Franklin WA, Prendergast FG, Murphy L, et al. 2008. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol. 39:498–505.
   PubMed Web of Science ®Google Scholar
• Sobot D, Mura S, Yesylevskyy SO, Dalbin L, Cayre F, Bort G, Mougin J, Desmaële D, Lepetre-Mouelhi S, Pieters G, et al. 2017. Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery. Nat Commun. 8:15678.
   PubMed Web of Science ®Google Scholar
• Song JJ, Liu J, Tolia NH, Schneiderman J, Smith SK, Martienssen RA, Hannon GJ, Joshua-Tor L. 2003. The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nat Struct Biol. 10(12):1026–1032.
   PubMedGoogle Scholar
• Spanarello S, La Ferla T. 2014. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol. 9:310–317.
   PubMedGoogle Scholar
• Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, Baker SD. 2003. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin Cancer Res. 9:151–159.
   PubMed Web of Science ®Google Scholar
• Sriprayoon T, Mahidol C, Ungtrakul T, Chun-On P, Soonklang K, Pongpun W, Laohapand C, Dechma J, Pothijaroen C, Auewarakul C, et al. 2017. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial. Hepatol Res. 47:E161–E168.
   PubMed Web of Science ®Google Scholar
• Staben LR, Koenig SG, Lehar SM, Vandlen R, Zhang D, Chuh J, Yu SF, Ng C, Guo J, Liu Y, et al. 2016. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nat Chem. 8:1112–1119.
   PubMed Web of Science ®Google Scholar
• Su D, Ng C, Khosraviani M, Yu SF, Cosino E, Kaur S, Xu K. 2016. Custom-designed affinity capture LC-MS F(ab’)2 assay for biotransformation assessment of site-specific antibody drug conjugates. Anal Chem. 88:11340–11346.
   PubMed Web of Science ®Google Scholar
• Sudimack J, Lee RJ. 2000. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 41:147–162.
   PubMed Web of Science ®Google Scholar
• Sun X, Widdison W, Mayo M, Wilhelm S, Leece B, Chari R, Singh R, Erickson H. 2011. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjugate Chem. 22:728–735.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, Nakanishi Y, Okamoto I. 2018. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 115:116–120.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Chari RV. 2011. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 17:6389–6397.
   PubMed Web of Science ®Google Scholar
• The Center for Drug Evaluation and Research (CDER). 2000. 21174 Mylotarg for Injection Pharmacology Review Part 2. [accessed 2000 Apr 14]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21174_MYLOTARG_pharmr_P2.pdf.
   Google Scholar
• Trubetskoy VS, Griffin JB, Nicholas AL, Nord EM, Xu Z, Peterson RM, Wooddell CI, Rozema DB, Wakefield DH, Lewis DL, et al. 2017. Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses. Nucleic Acids Res. 45:1469–1478.
   PubMed Web of Science ®Google Scholar
• Turecek PL, Bossard MJ, Schoetens F, Ivens IA. 2016. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 105:460–475.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Holá K, Šubr V, Bakandritsos A, Tuček J, Zbořil R. 2016. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem Rev. 116:5338–5431.
   PubMed Web of Science ®Google Scholar
• Unger C, Häring B, Medinger M, Drevs J, Steinbild S, Kratz F, Mross K. 2007. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res. 13:4858–4866.
   PubMed Web of Science ®Google Scholar
• Vadlapudi AD, Vadlapatla RK, Earla R, Sirimulla S, Bailey JB, Pal D, Mitra AK. 2013. Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): transporter recognition, tissue stability and antiviral activity. Pharm Res. 30:2063–2076.
   PubMed Web of Science ®Google Scholar
• van der Ploeg AT, Reuser AJ. 2008. Pompe's disease. Lancet. 372:1342–1353.
   PubMed Web of Science ®Google Scholar
• van Wijk GM, Hostetler KY, Kroneman E, Richman DD, Sridhar CN, Kumar R, van den Bosch H. 1994. Synthesis and antiviral activity of 3’-azido-3’-deoxythymidine triphosphate distearoylglycerol: a novel phospholipid conjugate of the anti-HIV agent AZT. Chem Phys Lipids. 70:213–222.
   PubMed Web of Science ®Google Scholar
• Vergote I, Leamon CP. 2015. Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors. Ther Adv Med Oncol. 7:206–218.
   PubMed Web of Science ®Google Scholar
• Veronese FM, editor. 2009. PEGylated protein drugs: basic science and clinical applications. Basel (Switzerland): Birkhäuser Verlag.
   Google Scholar
• Veronese FM, Caliceti P, Schiavon O. 1997. Branched and linear poly(ethylene glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J Bioact Compat Pol. 12:196–207.
   Web of Science ®Google Scholar
• Vlahov IR, Leamon CP. 2012. Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjugate Chem. 23:1357–1369.
   PubMed Web of Science ®Google Scholar
• Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, Leamon CP. 2006. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett. 16:5093–5096.
   PubMed Web of Science ®Google Scholar
• Vlahov IR, Santhapuram HK, You F, Wang Y, Kleindl PJ, Hahn SJ, Vaughn JF, Reno DS, Leamon CP. 2010. Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates. J Org Chem. 75:3685–3691.
   PubMed Web of Science ®Google Scholar
• Vu CB, Bemis JE, Benson E, Bista P, Carney D, Fahrner R, Lee D, Liu F, Lonkar P, Milne JC, et al. 2016. Synthesis and characterization of fatty acid conjugates of niacin and salicylic acid. J Med Chem. 59:1217–1231.
   PubMed Web of Science ®Google Scholar
• Vu CB, Bridges RJ, Pena-Rasgado C, Lacerda AE, Bordwell C, Sewell A, Nichols AJ, Chandran S, Lonkar P, Picarella D, et al. 2017. Fatty acid cysteamine conjugates as novel and potent autophagy activators that enhance the correction of misfolded F508del-cystic fibrosis transmembrane conductance regulator (CFTR). J Med Chem. 60:458–473.
   PubMed Web of Science ®Google Scholar
• Walles M, Rudolph B, Wolf T, Bourgailh J, Suetterlin M, Moenius T, Peraus G, Heudi O, Elbast W, Lanshoeft C, et al. 2016. New insights in tissue distribution, metabolism, and excretion of [3H]-labeled antibody maytansinoid conjugates in female tumor-bearing nude rats. Drug Metab Dispos. 44:897–910.
   PubMed Web of Science ®Google Scholar
• Widdison W, Wilhelm S, Veale K, Costoplus J, Jones G, Audette C, Leece B, Bartle L, Kovtun Y, Chari R. 2015. Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. Mol Pharm. 12:1762–1773.
   PubMed Web of Science ®Google Scholar
• Williams SP, Ogasawara A, Tinianow JN, Flores JE, Kan D, Lau J, Go M, Vanderbilt AN, Gill HS, Miao L, et al. 2016. ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1. Oncotarget. 7:25103–25112.
   PubMedGoogle Scholar
• Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, et al. 2003. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res. 9:3589–3597.
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, et al. 2007. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 25:1149–1157.
   PubMed Web of Science ®Google Scholar
• Zalipsky S, Saad M, Kiwan R, Ber E, Yu N, Minko T. 2007. Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action. J Drug Target. 15:518–530.
   PubMed Web of Science ®Google Scholar
• Zhai Y, Zhao Y, Lei J, Su Z, Ma G. 2009. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight. J Biotechnol. 142:259–266.
   PubMed Web of Science ®Google Scholar
• Zhang D, Luo G, Ding X, Lu C. 2012. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm Sin B. 2:549–561.
   Google Scholar
• Zhang M, Liu E, Cui Y, Huang Y. 2017. Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biol Med. 14:212–227.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Jiang JL, Gumlaw NK, Zhang J, Bercury SD, Ziegler RJ, Lee K, Kudo M, Canfield WM, Edmunds T, et al. 2009. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther. 17:954–963.
   PubMed Web of Science ®Google Scholar
• Zimmer M, Bista P, Benson EL, Lee DY, Liu F, Picarella D, Vega RB, Vu CB, Yeager M, Ding M, et al. 2017. CAT-2003: a novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. Hepatol Commun. 1:311–325.
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, et al. 2006. RNAi-mediated gene silencing in non-human primates. Nature. 441(7089):111–114.
   PubMed Web of Science ®Google Scholar